I still want LH gone after, all that suffering cou
Post# of 148187
A New Drug Shows Promise
Erlanson enrolled in a double-blind clinical trial of a drug called leronlimab, an experimental CCR5 inhibitor designed specifically for long COVID. Erlanson did not know whether she received the drug or a placebo until the study was unblinded, at which time she received confirmation that she did receive the drug. But she says that noticed a marked improvement in her condition about three days after she received her first dose on March 16.
“I was able to eliminate more than 24 symptoms,” Erlanson recalls. “I could think without it causing a headache. My lower body was not numb. This treatment got me out of my wheelchair, fixed the partial myoclonic jerks that I was having, and it fixed my nausea. I was able to cook, and my husband and kids were able to have a normal mom.”
CytoDyn, the company that manufactures leronlimab, said in a press release that their Phase 2 clinical trial showed a significant improvement in 18 of 24 long COVID symptoms studied in the non-placebo group. CytoDyn is working with the FDA to receive approval to proceed with a Phase 3 trial in the US. In the meantime, CytoDyn is conducting two Phase 3 trials of leronlimab in Brazil.
Erlanson has not received any doses of her trial medication since the first week of May, and since then, her symptoms have progressively returned. “I had forgotten how bad it was, and how much everything hurt. This drug is a shining light,” she says.